Michael Gelband ExodusPoint Capital Management
Michael Gelband is a co-founder of ExodusPoint Capital Management, a multi-strategy hedge fund launched by veterans of larger alternative platforms. The firm pursues diversified strategies across asset classes with a focus on risk-managed absolute returns. Gelband’s firm is followed as part of the newer generation of multi-strategy complexes.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$353M |
| 2 |
Microsoft
MSFT
|
+$352M |
| 3 |
Apple
AAPL
|
+$256M |
| 4 |
Alibaba
BABA
|
+$189M |
| 5 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$125M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SCHW
Charles Schwab
SCHW
|
+$82M |
| 2 |
Generac Holdings
GNRC
|
+$33.7M |
| 3 |
Pool Corp
POOL
|
+$32.5M |
| 4 |
Keurig Dr Pepper
KDP
|
+$31M |
| 5 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$25M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 14.28% |
| 2 | Consumer Discretionary | 10.77% |
| 3 | Healthcare | 5.09% |
| 4 | Industrials | 4.03% |
| 5 | Financials | 3.78% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
626
Titan International
TWI
$461M
| $1.63M | 0.02% |
+335,213
| New | +$1.38M |
|
627
Enovis
ENOV
$1.5B
| $1.62M | 0.02% |
+24,675
| New | +$1.44M |
|
628
Trade Desk
TTD
$6.19B
| $1.62M | 0.02% |
+20,280
| New | +$1.53M |
|
|
CVAC
629
CALL
DELISTED
CureVac
CVAC
| $1.62M | 0.02% |
+20,000
| New | +$1.53M |
|
630
Merck
MRK
$376B
| $1.62M | 0.02% |
20,752
+4,200
| +25% | +$321K |
|
631
Galicia Financial Group
GGAL
$6.66B
| $1.62M | 0.02% |
+184,994
| New | +$1.46M |
|
632
CALL
Veracyte
VCYT
$3.4B
| $1.61M | 0.02% |
+32,300
| New | +$1.5M |
|
633
Vanguard Information Technology ETF
VGT
$145B
| $1.61M | 0.02% |
+36,400
| New | +$1.5M |
|
|
VRAY
634
DELISTED
ViewRay, Inc.
VRAY
| $1.6M | 0.02% |
420,021
+154,185
| +58% | +$545K |
|
635
PUT
Xtrackers Harvest CSI 300 China A-Shares ETF
ASHR
$1.57B
| $1.6M | 0.02% |
+40,000
| New | +$1.5M |
|
|
MXIM
636
DELISTED
Maxim Integrated Products
MXIM
| $1.59M | 0.02% |
17,902
-23,937
| -57% | -$1.89M |
|
637
Tapestry
TPR
$26B
| $1.59M | 0.02% |
51,014
-77,515
| -60% | -$1.96M |
|
638
Nike
NKE
$60.5B
| $1.58M | 0.02% |
11,181
-27,328
| -71% | -$3.62M |
|
639
CALL
STAAR Surgical
STAA
$1.16B
| $1.58M | 0.02% |
+20,000
| New | +$1.46M |
|
640
Primerica
PRI
$9.1B
| $1.58M | 0.02% |
11,792
-3,632
| -24% | -$456K |
|
641
Graco
GGG
$13.1B
| $1.57M | 0.02% |
21,683
-124,844
| -85% | -$8.35M |
|
|
SUMO
642
DELISTED
Sumo Logic, Inc. Common Stock
SUMO
| $1.57M | 0.02% |
+54,820
| New | +$1.29M |
|
643
Whirlpool
WHR
$2.63B
| $1.57M | 0.02% |
+8,677
| New | +$1.66M |
|
|
CMA
644
DELISTED
Comerica
CMA
| $1.56M | 0.02% |
+28,002
| New | +$1.37M |
|
645
Spotify
SPOT
$110B
| $1.56M | 0.02% |
4,968
+3,955
| +390% | +$1.12M |
|
646
Fox Class A
FOXA
$28.8B
| $1.56M | 0.02% |
+53,637
| New | +$1.5M |
|
647
Iron Mountain
IRM
$36.3B
| $1.56M | 0.02% |
52,961
+44,652
| +537% | +$1.24M |
|
648
Stanley Black & Decker
SWK
$15.1B
| $1.56M | 0.02% |
+8,713
| New | +$1.55M |
|
|
KNDI
649
Kandi Technologies Group
KNDI
$64M
| $1.55M | 0.02% |
+225,000
| New | +$1.85M |
|
650
Omnicell
OMCL
$1.62B
| $1.55M | 0.02% |
+12,913
| New | +$1.27M |
|
Similar funds
Michael Gelband's Q4 2020 Portfolio in Review
As of Q4 2020, Michael Gelband held 2,600 positions worth $10.3B, up 105% from $5.02B the previous quarter. Its ten largest holdings account for 42% of the portfolio.
Michael Gelband deployed $4.62B of net new capital in Q4 2020, opening 918 new positions and adding to 493 existing holdings. Its largest new stake was State Street SPDR S&P 500 ETF Trust: 352,707 shares worth $132M.
By sector, the portfolio is most concentrated in Technology at 14% of assets, up from 11% a quarter earlier, followed by Consumer Discretionary and Healthcare.
On the sell side, the largest reduction was Charles Schwab, an estimated $82M trimmed.
- Michael Gelband's largest Q4 2020 buy was State Street SPDR S&P 500 ETF Trust: 352,707 shares worth $132M.
- Michael Gelband added most to Amazon in Q4 2020, an estimated $353M increase.
- Michael Gelband's biggest Q4 2020 reduction was Charles Schwab, cutting an estimated $82M.
- Michael Gelband fully exited Eli Lilly in Q4 2020, selling an estimated $21.7M.
- Michael Gelband's ten largest holdings make up 42% of its $10.3B portfolio in Q4 2020.
- Michael Gelband opened 918 new positions and closed 701 in Q4 2020.
- Michael Gelband's portfolio value rose 105% quarter-over-quarter to $10.3B.
Based on ExodusPoint Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.